|
|
|
|
||
|
||
|
Vol. 9, No. 1-24, pp. 1-808 Jan. 6, 2010 - Dec. 15, 2010 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
GENETIC DISCRIMINATION
– CRS report, 217
– EEOC final rule, 719 – Mont. rule, 382
– Advisory panel not renewed by HHS, 645
– Agricultural biotechnology, USDA agenda, 76 – Bioethics panel nominees, 247 – Biomarkers and surrogate endpoints, 345 – Biosimilars
– – Clinical trials urged, 486
– – Pathway, stakeholders comment, 721 – Commercial genetic test regulation, 484 – Death blamed on gene therapy (C.D. Ill.), 167 – Direct-to-consumer testing
– – FDA policy, 385
– – Regulation urged, 624 – – Risks and oversight, 556 – GINA – Informed consent issues, 618 – Maryland
– – Budget, biotechnology funding, 82
– – Construction of biotechnology facility, 253 – – Johns Hopkins pact with Montgomery County, 147 – Newborn screening
– – Guidance from HRSA, 277
– – Minn. newborn blood screening, 562 – – Neb. newborn screening, 26
– – Birth defects data system, 414
– – Centers of Excellence in Biomedicine and Health Care, 147
– – Australia, breast cancer gene patent challenge (Fed. Ct. Austl.), 367
– – Cornell, DNA patent claims (D. Del.), 342 – – Exception to infringement for gene patents, HHS report, 119 – – Isolated DNA, patent challenge (S.D.N.Y.), 103; patents invalid, Special Report, 228; webinar, Special Report, 353; notice of appeal, 398; recusal sought (Fed. Cir.), 477; brief filed, 515; BNA Insights, 594; comments, 652; briefs (Fed. Cir.), Special Report, 705 – – Licensing of diagnostics and therapeutics, 137 – – Myriad gene patent dispute with PTO (S.D.N.Y.), 40 – – Patentability of genetic sequences, BNA Insights, 428 – – Soya, patent protection for genetic modification, 445
– – House hearings, 343
– – Walgreens plans, 342 – Plant modifications, USDA auditing standard, 657 – Registry for genetic tests, NIH program, 210 – Synthetic biology
– – President's bioethics meeting, Special Report, 464
– – Recombinant DNA study sites, 427 – – Screening framework guidance from HHS, 649 – – Vaccines, House hearing, 339 – – Viral genome study limits, guidelines from NIH, 276 – UC Berkeley collection of freshman cell samples, 347; ban sought, 490; retooled, 522 – Vanderbilt databank of de-identified DNA samples, 47
– Alzheimer's study whistleblower suit (D. Mass.), 662; no evidence for falsity, 730
– Burnham Institute gets grant, 83 – Colleges receiving NIH grants, 247 – Conn., Alzheimer's and diabetes, 347 – Coordination by NIH and FDA, 134; public comment, 369 – DOD reimbursement rates rates, inconsistencies, 589 – E-health, SHARP grants, 217 – Exclusion of researcher, reinstatement of retaliation claim (6th Cir.), 87 – Fla. applications, 83; proposed rule, 148; grants, 694 – Fraud allegations (S.D.N.Y.), 27; reconsideration denied, 350; verdict challenged, 793 – Improper construction grant award by NIH, 387 – Innovation grants, 283 – Integrity studies, HHS grants, 145 – International IRB cooperation, 80 – Minority disparities, HHS university awards, 623 – New Jersey
– – Brain injuries, 55
– – Spinal cord research, 348; Sep. announcement, 628 – Stem cell research
See generally STEM CELL RESEARCH
– Therapeutic discovery project program, 717 – Training grant false claims (S.D.N.Y.), 526 – Univ. of Ill. SHARPS center, federal grant, 254 – Univ. of Medicine & Dentistry grant application (D.N.J.), 696
– Syphilis study, 607; findings recounted, 687; comments from CDC and NIH, 724
Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
